1. Home
  2. News and Media
  3. Latest News

Latest News

Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome ...

Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did N

Global HOPE, Teva and Direct Relief Partner to Bring Medicines to Help Improve the Lives of Children...

Global HOPE, Teva and Direct Relief Partner to Bring Medicines to Help Improve the Lives of Children with Cancer in Africa

New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion

New Report Shows Teva Generic Medicines Saved US Healthcare System $41.9 Billion

Teva Reports Fourth Quarter and Full Year 2019 Financial Results

Teva Reports Fourth Quarter and Full Year 2019 Financial Results

Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan

Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan

Teva Announces FDA Approval of AJOVY® (fremanezumab-vfrm) Injection Autoinjector

Teva Announces FDA Approval of AJOVY® (fremanezumab-vfrm) Injection Autoinjector

Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Gui...

Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Guidance

Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference

Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference

Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Note...

Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes

Teva Announces $1.5 Billion Debt Tender Offers

Teva Announces $1.5 Billion Debt Tender Offers

Teva Announces Launch of $1,500,000,000 Offering of Senior Notes

Teva Announces Launch of $1,500,000,000 Offering of Senior Notes

Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosi...

Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar

Teva Announces Appointment of New Chief Financial Officer

Teva Announces Appointment of New Chief Financial Officer

Teva Reports Third Quarter 2019 Financial Results

Teva Reports Third Quarter 2019 Financial Results

Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7,

Teva to Present New Analyses of Fremanezumab and Country-Specific Burden of Migraine at 24th World C...

Teva to Present New Analyses of Fremanezumab and Country-Specific Burden of Migraine at 24th World Congress of Neurology

Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation ...

Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019

Teva Announces Leadership Change in its Global Operations Group

Teva Announces Leadership Change in its Global Operations Group

Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Adv...

Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Advisory

Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to...

Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Trea

Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days...

Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Vers

Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-...

Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States

Teva Announces CFO Leadership Transition

Teva Announces CFO Leadership Transition

Teva Reports Second Quarter 2019 Financial Results

Teva Reports Second Quarter 2019 Financial Results

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 ...

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg)

Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus ...

Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus

Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection at the American Headache Society’s ...

Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection at the American Headache Society’s 61st

Teva to Host Conference Call to Discuss Second Quarter 2019 Financial Results at 8 a.m. ET on August...

Teva to Host Conference Call to Discuss Second Quarter 2019 Financial Results at 8 a.m. ET on August 7, 2

Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase ...

Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb

Teva Announces Launch of 1% Sodium Hyaluronate in the United States

Teva Announces Launch of 1% Sodium Hyaluronate in the United States

Teva Announces Launch of a Generic Version of Tracleer® (bosentan) Tablets in the United States

Teva Announces Launch of a Generic Version of Tracleer® (bosentan) Tablets in the United States

Teva to present new fremanezumab FOCUS Clinical Study Data for the first time at the 13th European H...

Teva to present new fremanezumab FOCUS Clinical Study Data for the first time at the 13th European Headac

Teva Announces Launch of a Generic Version of Ranexa® (ranolazine) Extended-Release Tablets in the U...

Teva Announces Launch of a Generic Version of Ranexa® (ranolazine) Extended-Release Tablets in the United States

Company Statement: Teva Reaches Agreement with State of Oklahoma to Resolve State’s Claims Against t...

Company Statement: Teva Reaches Agreement with State of Oklahoma to Resolve State’s Claims Against the Company

Teva Announces the Launch of a Generic Version of Delzicol® (mesalamine) Delayed-Release Capsules in...

Teva Announces the Launch of a Generic Version of Delzicol® (mesalamine) Delayed-Release Capsules in the United States

Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States

Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States

Teva to Present New Long-Term Data on Efficacy and Safety of Fremanezumab at 2019 American Academy o...

Teva to Present New Long-Term Data on Efficacy and Safety of Fremanezumab at 2019 American Academy of Neu

Teva Reports First Quarter 2019 Financial Results

Teva Reports First Quarter 2019 Financial Results

Teva Announces Launch of a Generic Version of Letairis® (ambrisentan) Tablets in the United States ...

Teva Announces Launch of a Generic Version of Letairis® (ambrisentan) Tablets in the United States

Teva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Aca...

Teva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Academy

Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 10...

Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg

Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache

Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache

Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the Unite...

Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United Sta

Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United ...

Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United State

Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, ...

Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019

Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Bot...

Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Qua

Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in t...

Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the Un